Clinical Trials
2 trialsNCT03486873 2026-06-05
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03953898 2026-06-01
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting